Exelixis (EXEL) Stock: Buy, Sell, or Hold?
EXEL - Exelixis Inc
$72.31
2.18 (3.11%)
▲
5d:
+10.65%
30d:
+22.87%
90d:
+27.53%
WAIT
LOW Confidence
Analysis Updated: Nov 3, 2026 12:00 AM ET
Earnings: Oct 29, 2026
0d
Get Alerted When EXEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: EXEL shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: EXEL shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$83.96
Based on 9.0% avg growth
INTRINSIC VALUE TODAY
$52.13
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EXEL is currently trading at $72.31, which is considered extended relative to its 30-day fair value range of $58.33 to $66.39. From a valuation perspective, the stock is trading at a premium (Forward PE: 16.9) compared to its historical average (12.8). At these levels, the market is pricing in 9.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EXEL is in a uptrend. The price is approaching resistance at $73.44. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: EXEL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $59.79. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EXEL is in a uptrend. The price is approaching resistance at $73.44. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: EXEL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $59.79. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$58.33 -
$66.39
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
18.1%
Protect Your Profits
EXEL is technically overbought (RSI 85). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+8.9% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- BEARISH: Trading 17.3% above Wall St target ($59.79)
- NEUTRAL: Trading at premium valuation - market expects 9.8% growth which is achievable
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$58.33 -
$66.39
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$63.91
Resistance Level
$73.44
Current Trend
Uptrend
Technical data as of
Nov 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.92
Wall Street Target
$59.79
(-17.3%)
Revenue Growth (YoY)
10.2%
Earnings Growth (YoY)
23.2%
Profit Margin
35.4%
Valuation Premium vs History
+9.8% premium
PE vs Historical
16.9 vs 12.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+9.8%
(market-implied from PE analysis)
1-Year Target
$79.40
(+10%)
2-Year Target
$87.18
(+21%)
3-Year Target
$95.72
(+32%)
3-Yr Target (if PE normalizes)
(PE: 17→13)
PE COMPRESSION
$72.43
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 14.0%)
$125.60
(+74%)
Base:
(SPY PE: 16.9, Growth: 14.0%)
$106.99
(+48%)
Bear:
(PE: 12.8, Growth: 14.0%)
$80.95
(+12%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 21.00 | Current EPS (TTM): $3.34
Bull Case
$98.72
(+37%)
Analyst growth 28.0%, PE expands to 23.1
Base Case
$89.75
(+24%)
Market implied 28.0%, PE stable at 21.0
Bear Case
$47.69
(-34%)
Severe decline -20.0%, PE contracts to 17.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: November 03, 2026 10:13 PM ET
Data refreshes hourly during market hours. Next update: 11:13 PM
Data refreshes hourly during market hours. Next update: 11:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EXEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$924 | 43 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 38 SELL |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
21 analysts |
$650 | 40 SELL |
|
NAMS
NewAmsterdam Pharma Comp… |
STRONG BUY
16 analysts |
$50 | 47 HOLD |
|
IMUX
Immunic Inc |
STRONG BUY
13 analysts |
$43 | 53 HOLD |
Advanced EXEL Option Strategies
Professional options setups generated by AI based on today's EXEL price and gamma walls.
